Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. Independent Director 2025 Annual Performance Report (Huang Zhixiong)
I, Huang Zhixiong, as an independent director of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company"), have strictly followed the "Company Law of the People's Republic of China," the "Securities Law of the People's Republic of China," the "Administrative Measures for Independent Directors of Listed Companies," and other laws, regulations, and normative documents, as well as the "Articles of Association" and the "Independent Director Work Rules" during my tenure. I have actively participated in the board and shareholder meetings of the Company, fully exercised my role as an independent director, faithfully performed my duties, and upheld the principle of protecting the interests of the Company and its shareholders, especially small shareholders. I have diligently performed my duties in 2025. The work report for 2025 is as follows:
I. Basic Information
Huang Zhixiong, male, born in February 1989, Chinese national, with no permanent right of abode overseas. He holds a Ph.D. in Accounting and is an Asset Appraiser. In 2022, he was awarded the title of Zhejiang Provincial Higher Education Young Leading Talent. He has served as a lecturer and associate professor at the School of Accounting, Zhejiang University of Finance and Economics. He is currently a professor and doctoral supervisor at the School of Accounting, Zhejiang University of Finance and Economics, and the Vice Dean of the International College of Zhejiang University of Finance and Economics. He has served as an independent director of the Company since February 7, 2025.
I possess the independence required by the "Administrative Measures for Independent Directors of Listed Companies" and other laws and regulations. I have conducted an annual independence self-assessment and found no circumstances that affect my independence.
II. Overview of Independent Director Performance in 2025
(I) Attendance at Board and Shareholder Meetings
In 2025, the Company held 9 board meetings and 4 shareholder meetings. My attendance during my tenure is as follows:
| Board Meeting Attendance | |||||||
|---|---|---|---|---|---|---|---|
| Number of Board Meetings Convened | Number of Board Meetings Attended | Number of Personally Attended Meetings | Number of Delegated Meetings | Number of Absent Meetings | Whether连续两次未亲自参加董事会会议 | Number of Shareholder Meetings Convened | Number of Shareholder Meetings Attended |
| 8 | 8 | 8 | 0 | 0 | No | 3 | 3 |
During my tenure in 2025, the convening and holding of the Company's board and shareholder meetings complied with legal requirements. Except for abstaining from voting on the remuneration proposal related to my own interests, I have prudently and meticulously reviewed all proposals at the board meetings I attended and voted in favor, with no opposing or abstaining votes.
(II) Participation in the Work of Special Board Committees and Independent Director Meetings
The Company's board has established four special committees: the Strategy Development Committee, the Audit Committee, the Nomination Committee, and the Remuneration and Assessment Committee. As the Chairman of the Audit Committee, the Chairman of the Remuneration and Assessment Committee, and the convener of the Independent Director Meetings, I have supervised and inspected the Company's various business activities in accordance with relevant laws, regulations, the "Articles of Association," the "Independent Director Work Rules," the "Audit Committee Work Rules," and the "Remuneration and Assessment Committee Work Rules." Based on the principle of diligence and responsibility, I have conscientiously performed my duties, strictly followed the implementation rules of each special committee, offered suggestions, and fully exercised my legal rights and obligations.